Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

doi:10.1200/JCO.2009.27.2997

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Aug 2010

Hennessy Bryan T J, Timms Kirsten M, Carey Mark S, Gutin Alexander, Meyer Larissa A, Flake Darl D, Abkevich Victor, Potter Jennifer, Pruss Dmitry, Glenn Pat, Li Yang, Li Jie, Gonzalez-Angulo Ana Maria, McCune Karen Smith, Markman Maurie, Broaddus Russell R, Lanchbury Jerry S, Lu Karen H, Mills Gordon B

Abstract excerpt

PURPOSE: The prevalence of BRCA(1/2) mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs. PATIENTS AND METHODS: In 235 unselected ovarian cancers, BRCA(1/2) was sequenced in 235, assessed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 20606085
DOI: 10.1200/JCO.2009.27.2997
PMCID: PMC2917312

Genes

BRCA1
BRCA2
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.PMID 20606085Read ↗

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsSemantic proximity Read ↗

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar populationSemantic proximity Read ↗

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.Semantic proximity Read ↗

Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.Semantic proximity Read ↗

BRCA mutations: Implications of genetic testing in ovarian cancer.Semantic proximity Read ↗

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancerSemantic proximity Read ↗

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.Semantic proximity Read ↗

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.Semantic proximity Read ↗

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.Semantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.